Revelation Biosciences up on license deal for infection drug
06/10/2022 14:03
** Drug developer Revelation Biosciences Inc's shares
REVB.O jump 45.6% to $0.37 premarket
** Co announces exclusive worldwide license agreement with
Vanderbilt University to develop and commercialize drug for
treating or preventing infections resulting from surgery, severe
burns, and antibiotic resistance urn:newsml:reuters.com:*:nBw4717nfa
** The drug, PHAD, has shown to significantly reduce the
duration and severity of infection in an animal study
** According to CDC, about 687,000 cases of infection in
acute care setting are reported, resulting in death of 72,000 -
REVB
** Up to Wednesday's close, stock lost ~98% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))